Immediate Versus Deferred Systemic Therapy in Patients With Mesothelioma
Sabine Schmid(University of Bern), Penelope A. Bradbury(University Health Network), Natasha B. Leighl(Princess Margaret Cancer Centre), M. Chowdhury(Princess Margaret Cancer Centre), Khaleeq Khan(Princess Margaret Cancer Centre), Laura Donahoe(University Health Network), Adrian G. Sacher(Princess Margaret Cancer Centre), Fatemeh Zaeimi(University Health Network), Marc de Perrot(University Health Network), Miguel García-Pardo(Hospital Universitario Ramón y Cajal), Luna Jia Zhan(University Health Network), Frances A. Shepherd(University Health Network), Geoffrey Liu(Princess Margaret Cancer Centre), John Cho(University Health Network), Michael Herman, Devalben Patel(University Health Network), Kristen Dietrich(University Health Network), Ronald Feld(University Health Network)
Cited by 2
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k